Paula Swain - Incyte Executive Resources

INCY Stock  USD 56.97  0.15  0.26%   

Executive

Ms. Paula J. Swain is the Executive Vice President Human Resources of Incyte Corporationrationration. She has served as Executive Vice President, Human Resources since August 2002 and joined Incyte as Senior Vice President of Human Resources in January 2002. Ms. Swain served as Senior Vice President of Human Resources at BristolMyers Squibb Company from October 2001 to January 2002, after it acquired DuPont Pharmaceuticals Company. From July 1998 to October 2001, Ms. Swain was Senior Vice President of Human Resources at DuPont Pharmaceuticals. From October 1992 to July 1998, Ms. Swain held a variety of human resources positions of increasing responsibility at DuPont Pharmaceuticals since 2002.
Age 66
Tenure 22 years
Address 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Phone302 498 6700
Webhttps://www.incyte.com
Swain received her B.A. in Psychology and Industrial Relations from Rockhurst University.

Incyte Management Efficiency

The company has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.12 in 2024. Return On Assets is likely to rise to 0.09 in 2024. At this time, Incyte's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 2.2 B in 2024, whereas Intangible Assets are likely to drop slightly above 74.2 M in 2024.
The company currently holds 38.29 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Incyte has a current ratio of 3.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Incyte until it has trouble settling it off, either with new capital or with free cash flow. So, Incyte's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Incyte sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Incyte to invest in growth at high rates of return. When we think about Incyte's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Hilary DixonMiMedx Group
N/A
Edward CarrDianthus Therapeutics
55
Douglas CPAMiMedx Group
58
Roland DeAngelisVericel Corp Ord
N/A
Patrick HelfrichVericel Corp Ord
N/A
Scott MBADianthus Therapeutics
N/A
Kate SurdezMiMedx Group
N/A
Judson TaylorDianthus Therapeutics
N/A
John LeonardVaccinex
77
Ross TuboVericel Corp Ord
54
Ernest SmithVaccinex
52
Vinita KumarMirum Pharmaceuticals
N/A
Kim FoxMilestone Pharmaceuticals
N/A
Eric BurnsVericel Corp Ord
N/A
Adam EsqDianthus Therapeutics
38
Scott TurnerMiMedx Group
58
Jonathan HopperVericel Corp Ord
52
Heidi HassenVericel Corp Ord
N/A
Patrick FowlerVericel Corp Ord
N/A
Alexandra HadenMiMedx Group
42
William IVMiMedx Group
50
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2094 people. Incyte (INCY) is traded on NASDAQ Exchange in USA. It is located in 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 and employs 2,524 people. Incyte is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Incyte Leadership Team

Elected by the shareholders, the Incyte's board of directors comprises two types of representatives: Incyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Incyte. The board's role is to monitor Incyte's management team and ensure that shareholders' interests are well served. Incyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Incyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
Steven Stein, Senior Vice President and Chief Medical Officer
Paul Trower, Principal Accounting Officer and VP of Fin.
Thomas Tray, Chief Finance
Pamela Murphy, Vice Communications
Eric Siegel, Executive Vice President General Counsel
Vijay Iyengar, Executive Vice President Global Strategy and Corporate Development`
Reid Huber, Chief Scientific Officer and Executive VP
Richard Levy, Executive Vice President Chief Drug Development and Medical Officer
Christine Chiou, Head Relations
PharmD MBA, Executive America
JeanJacques Bienaime, Independent Director
Paul Brooke, Independent Director
Maria Pasquale, Executive Vice President General Counsel
Christiana Stamoulis, CFO, Executive Vice President
Steven MD, Executive Officer
Julian Baker, Independent Vice Chairman of the Board
Sheila Denton, Executive Counsel
Michael Booth, VP - Investor Relations
David Gryska, CFO, Executive Vice President
Paul Friedman, Director
Wenqing Yao, Executive Vice President - Discovery Medicinal and Process Chemistry
Jacqualyn Fouse, Director
Paula Swain, Executive Resources
Paul Clancy, Director
Wendy Dixon, Independent Director
Michael Morrissey, Executive Operations
Herve Hoppenot, Chairman, CEO and President and Member of Non-Management Stock Option Committee
Barry Flannelly, Executive Vice President - Business Development and Strategic Planning
Dashyant Dhanak, Executive Vice President Chief Scientific Officer
Christiana MBA, Executive CFO
Maria JD, Gen VP
MBA MBA, Ex America

Incyte Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Incyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Incyte offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Incyte's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Incyte Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Incyte Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.
Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Incyte Stock analysis

When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
6.324
Earnings Share
2.65
Revenue Per Share
16.526
Quarterly Revenue Growth
0.093
Return On Assets
0.0646
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.